

References

1. Nikiforov VV, Suranova TG, Mironov AYU. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention: teaching aid. Moscow: Publishing House of the Academy of Postgraduate Education FMBA; 2020 (In Russ).
2. Micah AE, Cogswell IE, Cunningham B, et al. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. *The Lancet*. 2021;398(10308):1317–1343. doi: 10.1016/S0140-6736(21)01258-7.
3. Ibrahim M, Areej N, Pradipta P, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. *Hum Vaccin Immunother*. 2022;3:1–20. doi: 10.1080/21645515.2022.2027160
4. Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. *J Med Virol*. 2022;1–8. doi: 10.1002/jmv.27588
5. Brentville VA, Vankemmelbeke M, Metheringham RL, et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants. *bioRxiv*. 2021;6(18):448932. doi: 10.1101/2021.06.18.448932.
6. Kuzmina LP, Shigan EE, Briko NI et al. editors. Novel coronavirus infection COVID-19: professional aspects of health care and safety of medical workers: guidelines. 2nd ed. Moscow: AMT, FGBNU «NII MT»; 2022 (In Russ).
7. Abdulla ZA, Al-Bashir SM, Al-Salih NS, et al. Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. *Pathogen*. 2021;10(7):788. doi: 10.3390/pathogens10070788
8. Noh JY, Jeong HW, Shin EC. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. *Sig Transduct Target Ther*. 2021;6:203. doi: 10.1038/s41392-021-00623-2
9. Kharchenko EP. Vaccines against Covid-19: Comparison, Limitations, the Decrease of Pandemic and the Perspective of Viral Respiratory. *Epidemiology and Vaccinal Prevention*. 2021;20(1):4–19 (In Russ.). doi: 10.31631/2073-3046-2021-20-1-4-19
10. Vitello A, Ferrara F, Troiano V, et al. COVID-19 vaccines and decreased transmission of SARS-CoV-2. *Inflammopharmacol*. 2021;29:1357–1360. doi:10.1007/s10787-021-00847-2
11. Order of the Ministry of Health of Russia N1122n of 06December2021. «On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations for epidemic indications and the procedure for conducting preventive vaccinations». Moscow, 2021 (In Russ).
12. Kudlay D, Svistunov A. COVID-19 Vaccines: An Overview of Different Platforms. *Bioengineering*. 2022;9(2):72. doi: 10.3390/bioengineering9020072.
13. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines. *Sci Immunol*. 2021;6(59):1750. doi: 10.1126/sciimmunol.abj1750
14. Chang X, Augusto GS, Liu X, et al. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. *Allergy*. 2021; 76(9):2895–2998. doi: 10.1111/all.14893
15. Callaway E. Delta coronavirus variant: scientists brace for impact. *Nature*. 2021;595(7865):17–18. doi: 10.1038/d41586-021-01696-3
16. Ikegame S, Siddiquey MNA, Hung CT, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. *Nat Commun*. 2021;12(1):4598. doi: 10.1038/s41467-021-24909-9
17. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet*. 2021;397(10269):72–74. doi: 10.1016/S0140-6736(20)32623-4
18. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577

Об авторах

- **Ольга Анатольевна Рябцева** – к. м. н., врач-отоларинголог, врач высшей категории, ФГБОУ ВО РостГМУ Минздрава России. +7 (863) 264-35-81, ryabceva_oa@rostgmu.ru. ORCID: 0000-0003-3701-2753.
- **Петр Владимирович Цыганков** – проректор по лечебной работе ФГБОУ ВО РостГМУ Минздрава России, заведующий клиникой, ассистент кафедры хирургических болезней № 2. +7 (918) 557-86-74, pete7016@gmail.com. ORCID: 0000-0002-8444-1406.
- **Сергей Владимирович Шлык** – д. м. н., профессор, ректор, заведующий кафедрой терапии ФГБОУ ВО РостГМУ Минздрава России. +7 (863) 250-42-00, shlyk_sw@rostgmu.ru. ORCID: 0000-0003-3070-8424.
- **Галина Георгиевна Харсеева** – д.м.н., профессор, зав. кафедрой микробиологии и вирусологии №2 ФГБОУ ВО РостГМУ Минздрава России. +7 (863)250-41-09, galinagh@bk.ru. ORCID: 0000-0002-6226-2183.
- **Анна Владимировна Чепусова** – к.м.н., доцент кафедры микробиологии и вирусологии №2 ФГБОУ ВО РостГМУ Минздрава России. +7 (863)250-41-09, anutka_drum@mail.ru. ORCID: 0000-0002-4490-7013.

Поступила: 04.06.2022. Принята к печати: 10.10.2022.

Контент доступен под лицензией CC BY 4.0.

About the Authors

- **Olga A. Ryabtseva** – Cand. Sci. (Med.), otolaryngologist, doctor of the highest category of Rostov State Medical University. +7 (863) 264-35-81, ryabceva_oa@rostgmu.ru. ORCID: 0000-0003-3701-2753.
- **Petr V. Tsygankov** – Vice rector for clinical work, head of clinic, assistant of the surgical diseases chair № 2 of Rostov State Medical University. +7 (918) 557-86-74, pete7016@gmail.com. ORCID: 0000-0002-8444-1406.
- **Sergey V. Shlyk** – Dr. Sci. (Med.), Professor, Rector of the Department of Therapy of Rostov State Medical University. +7 (863) 250-42-00, shlyk_sw@rostgmu.ru. ORCID: 0000-0003-3070-8424.
- **Galina G. Kharseeva** – Dr. Sci. (Med.), Professor, Head of the Department of Microbiology and Virology №2 of Rostov State Medical University. +7 (863) 250-41-09, galinagh@bk.ru. ORCID: 0000-0002-6226-2183.
- **Anna V. Chepusova** – Cand. Sci. (Med.), Associate Professor of the Department of Microbiology and Virology № 2 of Rostov State Medical University. +7 (863) 250-41-09, anutka_drum@mail.ru. ORCID: 0000-0002-4490-7013.

Received: 04.06.2022. Accepted: 10.10.2022.

Creative Commons Attribution CC BY 4.0.

ПОЗДРАВЛЯЕМ!

Члена редколлегии
ИРИНУ ВИКТОРОВНУ ФЕЛЬДБЛЮМ
сердечно поздравляем с присуждением звания
Заслуженного деятеля науки Российской Федерации!

**Желаем Вам крепкого здоровья,
благополучия, новых творческих успехов
и достижений на поприще
эпидемиологической науки!**